Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

PRS REIT Q4 home completions, estimated rental values grow

(Sharecast News) - Real estate investment trust PRS REIT said on Monday that both home completions and estimated rental value had grown in the three months ended 30 June. PRS said its portfolio was fully completed and amounted to a total of 5,478 rental homes as of 30 June, with an estimated rental value of £72.0m per annum, up from 5,396 and £65.1m, respectively.

The FTSE 250-listed outfit stated its portfolio's performance "remains very strong", with rent collection in the period coming to 99% and physical occupancy at 96%, with 5,242 of the 5,478 completed homes occupied. PRS noted that a further 89 homes were reserved for applicants who had passed referencing and paid rental deposits but had not yet moved in. Including this cohort, occupancy at 30 June was 97%.

Like-for-like rental growth on stabilised sites was 9.6%, down from 11.7% a year earlier. Affordability was also said to have continued to be favourable at roughly 24%.

"The board expects to declare an interim quarterly dividend in respect of the fourth quarter of the financial year ended 30 June 2025 in early August 2025," added PRS.

As of 0845 BST, PRS shares were up 0.21% at 107.22p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.